Physician profile
Keith Murdock
NPI 1275945834
$1,564.91
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $352 · 2021: $639.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.26 | 2019-2021 | |
| Pfizer INC. | $393.73 | 2019-2021 | |
| Abbott Laboratories | $150.77 | 2021 | |
| Amgen INC. | $89.37 | 2020-2021 | |
| Astellas Pharma US INC | $75.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.73 | 2019 | |
| Gilead Sciences, INC. | $47.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Lantheus Medical Imaging, INC. | $23.15 | 2019 | |
| Akcea Therapeutics, INC. | $15.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Murdock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.